

# c-Myc/MYC/MRTL ABfinity™ Recombinant



## Rabbit Monoclonal Antibody – Purified

Catalog no. 700648

(See product label for lot information)

**Clone/PAD:** 27H46L35  
**Isotype:** IgG  
**Gene ID:** 4609  
**Protein Acc. no.:** P01106  
**Qty:** 100 µg  
**Volume:** 200 µl  
**Concentration:** 0.5 mg/mL

### Formulation

PBS + 0.09% sodium azide

### Application

For use in Western Blotting

### Reactivity

This antibody is specific for human c-myc

### Immunogen

Recombinant protein

### Immunogen sequence

Amino acids 1-164, 401-439.

### Expected Reactivity

Based on sequence identity and similarity, reactivity to Mouse is expected.

### Storage

2-8°C for up to 1 month, -20°C for long term storage. Avoid repeated freezing and thawing.

### Expiration Date

Expires one year from date of receipt when stored as instructed.

### Background

c-Myc is a member of a family of closely related genes which also includes N-myc, L-myc, P-myc, R-myc, S-myc, and B-myc (1). It was first identified as a protooncogene that was involved in the formation of leukemias (1, 2). c-myc protein is involved in the control of cell proliferation, transformation and differentiation (1, 3). This protein is expressed during embryonic development and is amplified and/or overexpressed in variety of tumors (4). The cellular localization of this protein is predominantly nuclear (5).

### References

1. DePinho, R.A., et al. (1991) myc family oncogenes in the development of normal and neoplastic cells. *Adv. Cancer Res.* 57:1-46.
2. Evan, G.I., et al. (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol. Cell. Biol.* 5(12):3610-3616.
3. Lukas, J., et al. (1996) Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. *Mol. Cell. Biol.* 16(3):1047-1057.
4. Gosney, J.R., et al. (1990) c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types. *Anticancer Res.* 10(3):623-628.
5. Steiner, P., et al. (1995) Identification of a myc-dependent step during the formation of active G1 cyclin-cdk complexes. *The EMBO Journal* 14(19):4814-4826.

Following applications had been tested during development. To make sure the consistency and reliability in the future lots, each lot is tested with antigen ELISA for specificity and potency. Each lot is also tested with SDS-PAGE, to ensure high purity.


### Applications:

	Species	Test Material	Concentration
Western Blotting	Human	Jurkat	1-2 µg/ml

**For Research Use Only. Not for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 7335 Executive Way • Frederick • MD 21704 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)



**Western Blot of c-Myc labeled with c-Myc Rabbit Recombinant Monoclonal Antibody (Cat. No. 700648)**

c-Myc Rabbit Recombinant Monoclonal Antibody (1 µg/ml) was used to label c-Myc in Jurkat Cell Lysate (30 µg/lane). The western was performed using the WesternBreeze® kit with NBT/BCIP as the substrate (Cat. No.WB7105).

**Explanation of symbols**

Symbol	Description	Symbol	Description
	Catalogue Number		Batch code
	Research Use Only		<i>In vitro</i> diagnostic medical device
	Use by		Temperature limitation
	Manufacturer		European Community authorised representative
	Without, does not contain		With, contains
	Protect from light		Consult accompanying documents
	Directs the user to consult instructions for use (IFU), accompanying the product.		

**For Research Use Only. Not for human or animal therapeutic or diagnostic use.**

[www.invitrogen.com](http://www.invitrogen.com)

Invitrogen Corporation • 7335 Executive Way • Frederick • MD 21704 • Tel: 800.955.6288 • E-mail: [techsupport@invitrogen.com](mailto:techsupport@invitrogen.com)